Incyte (INCY) EBT Growth (3y) (2013 - 2026)
Incyte (INCY) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 86.16% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 41.79% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 95.61% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 38.36% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 64.03% |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 39.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.37% |
| Mar 31, 2026 | 87.82% |
| Dec 31, 2025 | 69.12% |
| Sep 30, 2025 | 48.06% |
| Jun 30, 2025 | 34.49% |
| Mar 31, 2025 | 49.18% |
| Dec 31, 2024 | 37.75% |
| Sep 30, 2024 | -9.26% |
| Jun 30, 2024 | -62.25% |
| Mar 31, 2024 | 50.47% |
| Dec 31, 2023 | 17.25% |
| Sep 30, 2023 | 309.46% |
| Jun 30, 2023 | -3.33% |
| Mar 31, 2023 | 27.52% |
| Dec 31, 2022 | -13.83% |
| Sep 30, 2022 | 0.13% |
| Jun 30, 2022 | 28.28% |
| Mar 31, 2022 | -12.17% |
| Dec 31, 2021 | 19.28% |
| Sep 30, 2021 | 89.10% |